Guerbet Optimizes its Industrial Network / Sale of the Montreal pharmaceutical site
July 15 2020 - 12:00PM
Guerbet Optimizes its Industrial
NetworkSale of the Montreal pharmaceutical site
Villepinte (France), July 15, 2020 -
18:00 CET - Guerbet (GBT) today announced the sale of its
pharmaceutical site in Montreal (Canada) to MedXL, a specialist in
medical devices and sterile pre-filled syringes.
The Montreal industrial facility specializes on
the one hand in filling and finishing of contrast media and on the
other in the large-series manufacture of syringes pre-filled with
sterile solutions for third parties, which is not a core business
for Guerbet. Guerbet will gradually transfer its contrast agent
production, carried out previously in Montreal, to its
pharmaceutical sites in France and the USA.
Guerbet sells this site as part of its plans to
optimize its industrial network. The operation will make Guerbet
more competitive by improving capacity utilization at its other
manufacturing sites.
Guerbet is very happy about this transaction
with MedXL, under which all 240 of its employees will keep their
job. MedXL will use the Montreal site to step up its development in
response to the structural growth of the sterile pre-filled
syringes market.
The Montreal site will continue manufacturing
contrast media for Guerbet’s X-Ray range for at least two
years.
“Guerbet is delighted with this agreement with
MedXL, a partner committed to sustainable growth that has chosen to
invest in an efficient industrial site and high-quality team.
Thanks to this sale we can optimize capacity utilization at our
three pharmaceutical sites, which produce products for Guerbet
alone. This will help us to continuously improve our
competitiveness and give us the means to accelerate our growth,”
said Jean-François Blanc, VP Technical Operations at Guerbet.
Under this agreement, MedXL will become the
owner of the site from July 16 and the Montreal management team
will report to Paul Parisien, CEO of MedXL.
About
Guerbet
Guerbet is a leader in medical imaging
worldwide, offering a wide range of pharmaceutical products,
medical devices, digital and AI solutions for diagnostic and
interventional imaging, to improve the diagnosis and treatment of
patients. A pioneer since more than 90 years in the field of
contrast media with over 2,800 people globally, Guerbet is
continuously innovating with 9% of revenue dedicated to Research
& Development and four centers in France, Israel and the United
States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid
caps) and generated €817 million in revenue in 2019. For more
information about Guerbet, please visit www.guerbet.com.
About
MedXL
MedXL is a Canadian company that designs and
manufactures medical devices and sterile pre-filled syringes for
the pharmaceutical and surgical care industries. MedXL has been
established in Montreal (Canada) for 28 years, has 150 employees,
and distributes its complete range of products through a network of
distributors in more than 60 countries in Europe, North Africa and
the Americas. For more information about MedXL, please visit
www.medxl.com.
Media
Relations
Guerbet GlobalAlize RPCaroline
Carmagnol +33 (0)6 64 18 99 59 / guerbet@alizerp.com
- Guerbet Press Release-Montreal-July 15 2020
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Nov 2023 to Nov 2024
